4'-Methoxy-α-pyrrolidinopropiophenoneScript error: No such module "TemplatePar".Expression error: Unexpected < operator.
|Systematic (IUPAC) name|
233.305 g/mol[[Script error: No such module "String".]]|
Script error: No such module "collapsible list".|
4'-Methoxy-α-pyrrolidinopropiophenone (MOPPP) is a stimulant drug. It is structurally related to α-PPP in the same way that PMA is related to amphetamine: a methoxy group has been added to the 4-position on the phenyl ring. MOPPP was sold in Germany as a designer drug in the late 1990s and early 2000s, along with a number of other pyrrolidinophenone derivatives, although it has never achieved the same international popularity as its better-known relations α-PPP and MDPV.
Cite error: Invalid
parameter "group" is allowed only.
<references group="..." />
- ↑ Springer D, Fritschi G, Maurer HH. Metabolism and toxicological detection of the new designer drug 4'-methoxy-alpha-pyrrolidinopropiophenone studied in rat urine using gas chromatography-mass spectrometry. Journal of Chromatography B. Analytical Technologies in the Biomedical and Life Sciences. 2003 Aug 15;793(2):331-42. PMID 12906908
- ↑ Springer D, Staack RF, Paul LD, Kraemer T, Maurer HH. Identification of cytochrome P450 enzymes involved in the metabolism of 4'-methoxy-alpha-pyrrolidinopropiophenone (MOPPP), a designer drug, in human liver microsomes. Xenobiotica. 2003 Oct;33(10):989-98. PMID 14555336
- ↑ Springer D, Fritschi G, Maurer HH. Metabolism of the new designer drug alpha-pyrrolidinopropiophenone (PPP) and the toxicological detection of PPP and 4'-methyl-alpha-pyrrolidinopropiophenone (MPPP) studied in rat urine using gas chromatography-mass spectrometry. Journal of Chromatography B. Analytical Technologies in the Biomedical and Life Sciences. 2003 Nov 5;796(2):253-66. PMID 14581066
- ↑ Maurer HH, Kraemer T, Springer D, Staack RF. Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone types: a synopsis. Therapeutic Drug Monitoring. 2004 Apr;26(2):127-31. PMID 15228152
- ↑ Staack RF, Maurer HH. Metabolism of designer drugs of abuse. Current Drug Metabolism. 2005 Jun;6(3):259-74. PMID 15975043